Management of Type 2 Diabetes After Gastric Bypass Surgery
Primary Purpose
Diabetes Mellitus, Type 2
Status
Terminated
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Actrapid insulin+Gloucose
Actrapid insulin
Sponsored by

About this trial
This is an interventional supportive care trial for Diabetes Mellitus, Type 2 focused on measuring Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion Criteria:
- Body mass index (BMI) > 35,
- Insulin-requiring T2DM,
- Age >18yr,
- Having undergone gastric bypass surgery,
- HbA1C >8%
Exclusion Criteria:
- Non-insulin requiring T2DM,
- HbA1C <8%
Sites / Locations
- Imperial College London, Charing Cross Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Actrapid insulin
Actrapid insulin+Gloucose
Arm Description
Intensive glycaemic control Intervention: Actrapid insulin
conventional glycaemic control Intervention: Actrapid insulin+Glucose
Outcomes
Primary Outcome Measures
efficacy and safety of an intensive glycaemic protocol after bariatric surgery
insulin+Gloucose
Secondary Outcome Measures
Full Information
NCT ID
NCT01213563
First Posted
October 1, 2010
Last Updated
August 19, 2020
Sponsor
Imperial College London
1. Study Identification
Unique Protocol Identification Number
NCT01213563
Brief Title
Management of Type 2 Diabetes After Gastric Bypass Surgery
Official Title
Protocol Driven Management of Type 2 Diabetes After Gastric Bypass Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
August 2020
Overall Recruitment Status
Terminated
Why Stopped
Data were published that superseded this study.
Study Start Date
January 2009 (undefined)
Primary Completion Date
September 2010 (Actual)
Study Completion Date
September 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Imperial College London
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Gastric bypass surgery has been proposed as an effective treatment strategy for type 2 diabetes mellitus (T2DM), but thus far algorithms for the management of T2DM immediately after surgery have not been established. The investigators designed an algorithm to achieve good glycaemic control in patients with insulin-requiring T2DM upon discharge after gastric bypass surgery, and evaluated this algorithm for feasibility, efficacy, and safety.
Detailed Description
This is a prospective randomised controlled intervention study on obese human subjects with Type 2 Diabetes Mellitus undergoing obesity surgery (n=80). Patients will be recruited from those already due to undergo bariatric surgery within the context of the obesity clinic (Imperial College London). Patients will be randomised to either of two treatment protocols.
Protocol A-Conservative Management: On admission to hospital all pre-operative oral antidiabetic agents and insulin are stopped and glucose monitoring is carried out every four hours at the same time as routine observations. Actrapid insulin is administered with glucose as per standard sliding scale (Appendix A). Just prior to discharge, total insulin administered over the previous 24 hour post-operative period is calculated. Based on the results of ward based glucose monitoring, post-operative patients can be divided in two broad categories.
The first group includes patients who are able to maintain euglycaemia without exogenous insulin administration. These patients are discharged home on their preoperative Metformin dose and are advised to continue monitoring their fasting glucose levels at home. If fasting glucose levels of less than 4 or more than 10mmol/l are recorded at home, the patients are encouraged to contact the obesity clinic physicians for advice.
The second group includes patients experiencing hyperglycemic episodes in the immediate post-operative period. These patients are discharged home on their preoperative Metformin dose and once daily insulin Glargine as decided by the discharging doctor (or based on half their last 24 hour requirements) and are advised to continue monitoring their fasting glucose levels at home. If fasting glucose levels of less than 4 or more than 10mmol/l are recorded at home, the patients are encouraged to contact the obesity clinic physicians for advice.
Protocol B-Intensive management: On admission to hospital all pre-operative oral antidiabetic agents and insulin are stopped and glucose monitoring is carried out every four hours at the same time as routine observations. Actrapid insulin is administered as per standard sliding scales (appendix A). Just prior to discharge, total insulin administered over the previous 24 hour post-operative period is calculated. Based on the results of ward based glucose monitoring patients are discharged home on metformin 1000mg BID and/or the equivalent amount of Glargine insulin requirement in previous 24 hours prior to discharge. These patients are also advised to continue glucose monitoring at home and will be contacted every day and their medication adjusted to maintain a fasting glucose between 5 and 7mmol/l. When this is consistently achieved the investigators will stop calling, but patients will be encouraged to continue monitoring their blood sugars and contact the investigators should they experience any problems with their glycaemic control.
Venesection will take place at 10 days, 3, 6 and 12 months post-operatively and yearly thereafter for fasting glucose and HbA1c as part of the routine care of patients of the obesity clinic. As part of clinical management we will ensure that all patients with diabetes will have a kidney (2 samples of morning urine albumin creatinine ratio), nerve (nerve conduction study, including thermal threshold testing) and eye (retinal photograph) tests once before and within 1, 2 and 3 years after surgery. These tests are all non invasive and except from the nerve tests are performed routinely for all patients with diabetes at least yearly and if performed in the community they will not be repeated.Therefore, other than the nerve conduction studies, there will be no extra burden to the patients as a result of the study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
50 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Actrapid insulin
Arm Type
Experimental
Arm Description
Intensive glycaemic control Intervention: Actrapid insulin
Arm Title
Actrapid insulin+Gloucose
Arm Type
Active Comparator
Arm Description
conventional glycaemic control Intervention: Actrapid insulin+Glucose
Intervention Type
Drug
Intervention Name(s)
Actrapid insulin+Gloucose
Other Intervention Name(s)
insulin+Gloucose
Intervention Description
On admission to hospital all pre-operative oral antidiabetic agents and insulin are stopped and glucose monitoring is carried out every four hours at the same time as routine observations. Actrapid insulin+ Glucose is administered as per standard sliding scale (Appendix A). Just prior to discharge, total insulin administered over the previous 24 hour post-operative period is calculated. Based on the results of ward based glucose monitoring, post-operative patients can be divided in two broad categories.
Intervention Type
Drug
Intervention Name(s)
Actrapid insulin
Other Intervention Name(s)
insulin
Intervention Description
On admission to hospital all pre-operative oral antidiabetic agents and insulin are stopped and glucose monitoring is carried out every four hours at the same time as routine observations. Actrapid insulin is administered as per standard sliding scales (appendix A). Just prior to discharge, total insulin administered over the previous 24 hour post-operative period is calculated. Based on the results of ward based glucose monitoring patients are discharged home on metformin 1000mg BID and/or the equivalent amount of Glargine insulin requirement in previous 24 hours prior to discharge.
Primary Outcome Measure Information:
Title
efficacy and safety of an intensive glycaemic protocol after bariatric surgery
Description
insulin+Gloucose
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Body mass index (BMI) > 35,
Insulin-requiring T2DM,
Age >18yr,
Having undergone gastric bypass surgery,
HbA1C >8%
Exclusion Criteria:
Non-insulin requiring T2DM,
HbA1C <8%
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Carel W Le Roux, MD, PhD
Organizational Affiliation
Imperial College London
Official's Role
Principal Investigator
Facility Information:
Facility Name
Imperial College London, Charing Cross Hospital
City
London
ZIP/Postal Code
W68NA
Country
United Kingdom
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
22052198
Citation
Fenske WK, Pournaras DJ, Aasheim ET, Miras AD, Scopinaro N, Scholtz S, le Roux CW. Can a protocol for glycaemic control improve type 2 diabetes outcomes after gastric bypass? Obes Surg. 2012 Jan;22(1):90-6. doi: 10.1007/s11695-011-0543-6.
Results Reference
derived
Learn more about this trial
Management of Type 2 Diabetes After Gastric Bypass Surgery
We'll reach out to this number within 24 hrs